Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Raises Price Target to $37
Benzinga Newsdesk 9 months ago
NewsPrice TargetReiterationAnalyst Ratings
Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $27.5 to $37.
Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $27.5 to $37.